The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019, but could only be prescribed ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the ... 7.6% of participants taking the placebo. “When Johnson & Johnson started researching Spravato ...

A class action has been filed claiming a pharmaceutical giant sold and marketed in New Zealand cold medicines that did not ...

Phenylephrine is a commonly used ingredient in cold and flu medications as a nasal and sinus decongestant. It is present in several on-the-shelf cold and flu medications in New Zealand, including ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Australia-based JGA Saddler has filed a class action lawsuit against Johnson & Johnson NZ over its phenylephrine-based cold ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray ... Last year, drugmaker Johnson & Johnson shared data from another clinical trial comparing Spravato ...